Drugs / Deanxit
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02723903 | Dec 2015 → Dec 2020 | metabolic syndrome X | RenJi Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00841230 | Feb → Jul 2009 | tinnitus | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06945237 | Apr → Aug 2025 | gastroesophageal reflux disease | RenJi Hospital | Completed | No outcome recorded |
| — | NCT06931223 | Apr → Sep 2025 overdue | dyspepsia | RenJi Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deanxit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723903 ↗ |
| Known as | Flupentixol-Melitracen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06931223 ↗ |